Search Results
Sep 08, 2026, 03:02 ET Fujitsu develops diamond-spin quantum computer prototype
New diamond-spin quantum computer prototype incorporating tin-vacancy (SnV) centers into photonic integrated circuits marks significant step toward quantum computing scalabilityKAWASAKI, Japan, Sept. 8, 2026 /PRNewswire/
More news about: Fujitsu Limited
Sep 01, 2026, 09:00 ET BillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of Origin
182 patients with more than 17 solid tumor types, Northstar Select detected 51% more clinically actionable or pathogenic single nucleotide variant (SNV)/Indels and 109% more copy number variants (CNVs) than the aggregated results from available comparators, with 45% fewer null reports.4About
More news about: BillionToOne
Jun 29, 2026, 12:39 ET BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
182 patients with more than 17 solid tumor types, Northstar Select detected 51% more clinically actionable or pathogenic single nucleotide variant (SNV)/Indels and 109% more copy number variants (CNVs) than the aggregated results from available comparators, with 45% fewer null reports.²About Northstar
More news about: BillionToOne
May 21, 2026, 10:22 ET Volta Labs lance une solution automatisée de préparation de bibliothèques pour le kit de séquençage par ligature Oxford Nanopore V14
sur une seule cellule de flux PromethION, tout en offrant une précision de détection des variants de qualité diagnostique, avec un taux de rappel des SNV de 99,66 %.L'évaluation de l'UMC Utrecht, présentée lors de l'AGBT 2026, a confirmé que la solution intégrée de Callisto, combinant extraction
More news about: Volta Labs
May 21, 2026, 10:21 ET Volta Labs führt automatisierte Bibliotheksvorbereitungslösung für das Oxford Nanopore Ligation Sequencing Kit V14 ein
Gigabasen (Gb) auf einer einzigen PromethION-Fließzelle und lieferten gleichzeitig eine diagnostisch hochwertige Variantengenauigkeit mit 99,66 % SNV-Recall.Die Evaluierung des UMC Utrecht, die auf der AGBT 2026 vorgestellt wurde, bestätigte, dass die integrierte hochmolekulare DNA-Extraktion und
More news about: Volta Labs
May 21, 2026, 09:11 ET Volta Labs lanza una solución automatizada para la preparación de bibliotecas
120 gigabases (Gb) de salida en una sola celda de flujo PromethION, ofreciendo una precisión de variantes de grado diagnóstico con una recuperación de SNV del 99,66%.La evaluación del UMC Utrecht, presentada en AGBT 2026, confirmó que la extracción integrada de ADN de alto peso molecular y la preparación
More news about: Volta Labs
May 21, 2026, 09:05 ET Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14
libraries achieved up to 120 gigabases (Gb) of output on a single PromethION flow cell while delivering diagnostic-grade variant accuracy with 99.66% SNV recall.UMC Utrecht evaluation, presented at AGBT 2026, confirmed that Callisto's integrated high molecular weight DNA extraction and ligation-based
More news about: Volta Labs
May 21, 2026, 04:05 ET Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14
libraries achieved up to 120 gigabases (Gb) of output on a single PromethION flow cell while delivering diagnostic-grade variant accuracy with 99.66% SNV recall.UMC Utrecht evaluation, presented at AGBT 2026, confirmed that Callisto's integrated high molecular weight DNA extraction and ligation-based
More news about: Volta Labs
May 21, 2026, 03:14 ET Datar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue
sólidos. El ensayo analiza 517 genes asociados al cáncer y tiene como objetivo proporcionar información sobre variantes somáticas de un solo nucleótido (SNV), pequeñas inserciones y deleciones (InDels), amplificación del gen ERBB2 y fusiones genéticas que involucran a ALK, RET y ROS1. CellDx-Tissue
More news about: Datar Cancer Genetics
May 15, 2026, 10:00 ET Datar Cancer Genetics 的 CellDx-Tissue 獲得美國 FDA 核准，為該項利用 DNA 與 RNA 進行的實體腫瘤全方位基因體分析檢測寫下里程碑
CellDx-TissueCellDx-Tissue 是一種定性體外診斷 (IVD) 檢測，它利用標靶式次世代定序 (NGS) 技術，對從福爾馬林固定石蠟包埋 (FFPE) 實體腫瘤患者的腫瘤組織中分離的 DNA 及 RNA 進行分析。 此檢測分析 517 個與癌症相關的基因，目的在於提供有關體細胞單核苷酸變異 (SNV)、小片段插入和缺失 (InDels)、ERBB2 基因擴增與涉及 ALK、RET 和 ROS1 的基因融合資訊。 CellDx-Tissue 為單一實驗室檢測，由 Datar Cancer Genetics 旗下獲得 CAP 及 CLIA 認證的實驗室進行。重要意義全方位基因體分析已成為實體腫瘤臨床管理的核心組成部分，協助臨床醫生在多種癌症類型中全面解析腫瘤基因體變異。
More news about: Datar Cancer Genetics
May 15, 2026, 09:59 ET Datar Cancer Genetics reçoit l'autorisation de la FDA des États-Unis pour CellDx-Tissue, un test de profilage génomique complet pour les tumeurs solides utilisant l'ADN et l'ARN
des tumeurs solides. Le test analyse 517 gènes associés au cancer et vise à fournir des informations sur les variants somatiques à nucléotide unique (SNV), les petites insertions et délétions (InDels), l'amplification du gène ERBB2 et les fusions de gènes impliquant ALK, RET et ROS1.
More news about: Datar Cancer Genetics
Feb 10, 2026, 09:00 ET BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®
182 patients with more than 17 solid tumor types, Northstar Select detected 51% more clinically actionable or pathogenic single nucleotide variant (SNV)/Indels and 109% more copy number variants (CNVs) than available comparators, with 45% fewer null reports. When comparing matched CNV coverage between assays,
More news about: BillionToOne
Dec 23, 2025, 17:55 ET UiPath Set to Join S&P MidCap 400 and Versant Media Group to Join S&P SmallCap 600
changes to the S&P MidCap 400, S&P SmallCap 600: UiPath Inc. (NYSE: PATH) will replace Synovus Financial Corp. (NYSE: SNV) in the S&P MidCap 400 effective prior to the opening of trading on Friday, January 2. S&P MidCap 400 constituent Pinnacle Financial Partners
More news about: S&P Dow Jones Indices